Tecentriq Adverse Event Report 2018

$19.99

This report includes data from the FDA’s Adverse Events Reports for 2018.  We removed reports where the subject of the report was taking only this drug. This report provides the following fields:

  • ID
  • Patient Summary
  • Patient Gender
  • Patient Age
  • Drug Products
  • Drug Reactions

Description

Tecentriq (atezolizumab) is a monoclonal antibody that affects the actions of the body’s immune system. Atezolizumab strengthens your immune system to help your body fight against tumor cells. Tecentriq is used to treat a certain type of bladder cancer and urinary tract cancer that has spread to other parts of the body or cannot be removed by surgery. Your doctor may perform a biopsy to test your cancer for a protein called “PD-L1,” or a specific genetic marker (an abnormal “EGFR” or “ALK” gene). Tecentriq is used to treat non-small cell lung cancer that has spread to other parts of the body or cannot be removed by surgery. Tecentriq is used in combination with the medicine paclitaxel protein-bound to treat a type of breast cancer called triple-negative breast cancer (TNBC) that has spread to other parts of the body or cannot be removed by surgery, and tests positive for “PD-L1″, or a specific genetic marker (an abnormal “EGFR” or “ALK” gene). Tecentriq is also used to treat a type of lung cancer called small cell lung cancer (SCLC). Tecentriq is sometimes given after other cancer treatments have not worked or have stopped working.https://www.drugs.com/tecentriq.html

Contact US

484-352-2642

What is an Adverse Event Report?

The FDA Adverse Event Reporting System (FAERS) is a database that contains adverse event reports, medication error reports and product quality complaints resulting in adverse events that were submitted to FDA.